Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Invaplex AR-DETOX vaccine in healthy adults
NCT03869333Phase 1Completed
- Sponsor
- PATH
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of InvaplexAR-Detox in shigellosis (4 arms), sponsored by PATH. Primary endpoints: Percentage of Participants With Adverse Events, Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 1 and 3 more. Started Mar 2019; status: completed.
02
Drugs
InvaplexAR-Detox
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT03869333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869333.